NCT01919866Unknown1 期
Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 120
- 试验地点
- 7
- 主要终点
- Engraftment rate and transplant related mortality
研究概览
简要总结
Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with primary refractory or relapsed disease (including relapse after previous SCT and active disease)
- •AML in complete remission of refractory
- •MDS RAEB-t/secondary AML
- •Non-Hodgkin Lymphoma / Hodgkin Lymphoma
- •non malignant diseases (aplastic anemia, thalassemia, SCID)
- •relapsed Neuroblastoma
- •relapsed soft tissue sarcoma (Rhabdomyosarcoma, Ewing sarcoma, PNET
- •soft tissue sarcoma with primary bone metastases or bone marrow
- •in whom no matched donor was available,
排除标准
- •< 6 months after previous HSCT
- •active cerebral seizure conditions
- •massive progression of leukemias or solid tumours before planned trp.
- •left ventricular ejection fraction <25%
- •creatinine clearance <40ml/min before conditioning
- •respiratory insufficiency with oxygen demand or DLCO <30%
- •Bilirubin >4mg/dl, GOT/GPT >400
- •severe infection (HIV, Aspergillosis)
- •pregnancy
结局指标
主要结局
Engraftment rate and transplant related mortality
时间窗: 365 days
engraftment rate will be evaluated by leukocyte counts in peripheral blood . Definition of engraftment: \>500 neutrophiles/µl blood. Transplant related mortality will be evaluated at day 100 and day 365 post transplant
次要结局
- Graft versus Host disease and speed of immune reconstitution(365 days)
研究者
Peter Lang
Prof. Dr. med.
University Children's Hospital Tuebingen
研究点 (7)
Loading locations...
相似试验
终止
2 期
Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk DiseasesMalignant and Non-malignant High Risk DiseasesNCT00945126Johann Wolfgang Goethe University Hospital68
进行中（未招募）
1 期
Stem cell transplantation with stem cells from related and non-related donators in pediatric patients with and without malignant diseases.EUCTR2006-000393-76-DEJohann Wolfgang Goethe-Universität Frankfurt am Main
Unknown
2 期
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid TumorsOsteosarcomaSoft Tissue SarcomaNeuroblastomaEwing SarcomaRhabdomyosarcomaNCT01807468Samsung Medical Center12
已完成
1 期
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationLeukemia, B-cellLymphoma, HodgkinsLymphoma, Non-hodgkinsLymphoma, B-CellNCT01087294National Cancer Institute (NCI)85
Unknown
不适用
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell TransplantationCD19-chimeric Antigen Receptor T CellsRelapsed and/or Refractory Acute Lymphoblastic Leukemiathe Haploidentical Hematopoietic Stem Cell TransplantationNCT03423706First Affiliated Hospital of Harbin Medical University50